A Phase 3 Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate a Switch to Doravirine/Islatravir (DOR/ISL) Once-Daily in Participants with HIV-1 Virologically Suppressed on Bictegravir / Emtricitabine / Tenofovir / Alafenamide (BIC/FTC/TAF)

  • McMahon, James (Primary Chief Investigator (PCI))
  • Roney, Janine (Project Manager)

Project: Research

Project Details

StatusFinished
Effective start/end date21/06/20 → 31/12/22

Keywords

  • Infectious diseases
  • Human immunodeficiency virus (HIV)
  • Clinical trial